Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inverness to launch early HIV test in developing world

This article was originally published in Clinica

Executive Summary

Inverness Medical Innovations plans to launch its Determine HIV-1/2 Ag/AB Combo test in the developing world in the third quarter. The diagnostic can detect HIV infections earlier than current HIV antibody-only tests, the Waltham, Massachusetts firm said. It detects HIV p24 antigen, which is present during the first few weeks of HIV infection before HIV antibodies are produced, as well as antibodies for HIV-1 and -2. The point-of-care test can provide results in 20 minutes. Inverness unveiled it at the International AIDS Conference (AIDS 2008) in Mexico City last week, along with its Clearview TB ELISA, to detect TB in patients co-infected with HIV.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel